Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $35.00 | Outperform | Leerink Partners |
| 7/22/2024 | $24.00 | Hold → Buy | Jefferies |
| 7/18/2024 | $40.00 → $20.00 | Overweight → Neutral | JP Morgan |
| 7/10/2024 | $55.00 → $25.00 | Buy → Hold | Deutsche Bank |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | Buy → Neutral | Guggenheim | |
| 6/3/2024 | $24.00 | Hold | Jefferies |
| 5/1/2024 | $57.00 → $32.00 | Buy → Hold | TD Cowen |
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
PLEASANTON, Calif., Nov. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference on Tuesday, November 19, at 1:00 p.m. Eastern Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomic
Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS and PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches. Working alongside more than 50 medical institutions, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. By using V
PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables.Began shipping GEM-X Flex, setting a new standard for the cost per cell for researchers and enabling the
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $50 to $32.
Jefferies analyst Tycho Peterson upgrades 10x Genomics (NASDAQ:TXG) from Hold to Buy and maintains the price target from $24 to $24.
Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00
Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00
JP Morgan downgraded 10x Genomics from Overweight to Neutral and set a new price target of $20.00 from $40.00 previously
PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer
Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an
Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar
PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables.Began shipping GEM-X Flex, setting a new standard for the cost per cell for researchers and enabling the
PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024. Preliminary Select Third Quarter 2024 Results Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.Preliminary revenue by source for the third quarter is expected to be as follows:Instruments revenue of approximately $19.1 million, representing a 46
PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated m
10-Q - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)